Dr. Alejandro Duran Crane, MD

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 30 payments worth $15,596 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Ohio →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 1 companies. The companies reported $8,217 in research payments for these studies, mostly to the institutions running them.

• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT04255433
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
  Eli Lilly and Company · Completed · NCT05882045
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
  Eli Lilly and Company · Completed · NCT05929066
• A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
  Eli Lilly and Company · Completed · NCT05929079
• A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT06010004
• A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
  Eli Lilly and Company
• A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
  Eli Lilly and Company · Completed · NCT05931367
• A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  Eli Lilly and Company · Active, not recruiting · NCT04965493
• A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
  Eli Lilly and Company · Completed · NCT05931380
• A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  Eli Lilly and Company · Active, not recruiting · NCT05023980

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Cleveland

• Walid A. Abboud, MD
• Mandi Abdel Ahad, DO
• Bahaa M. Abdelghaffar, MD
• John Abdelnour, MD
• Nawal Abdi, MD
• Tariq Abdulkarim, M.D.
• Nabilah Abdullah, M.D
• Chaya Abelow, MD